Literature DB >> 26670047

Elevated CaMKIIα and Hyperphosphorylation of Homer Mediate Circuit Dysfunction in a Fragile X Syndrome Mouse Model.

Weirui Guo1, Laura Ceolin2, Katie A Collins1, Julie Perroy2, Kimberly M Huber3.   

Abstract

Abnormal metabotropic glutamate receptor 5 (mGluR5) function, as a result of disrupted scaffolding with its binding partner Homer, contributes to the pathophysiology of fragile X syndrome, a common inherited form of intellectual disability and autism caused by mutations in Fmr1. How loss of Fmr1 disrupts mGluR5-Homer scaffolds is unknown, and little is known about the dynamic regulation of mGluR5-Homer scaffolds in wild-type neurons. Here, we demonstrate that brief (minutes-long) elevations in neural activity cause CaMKIIα-mediated phosphorylation of long Homer proteins and dissociation from mGluR5 at synapses. In Fmr1 knockout (KO) cortex, Homers are hyperphosphorylated as a result of elevated CaMKIIα protein. Genetic or pharmacological inhibition of CaMKIIα or replacement of Homers with dephosphomimetics restores mGluR5-Homer scaffolds and multiple Fmr1 KO phenotypes, including circuit hyperexcitability and/or seizures. This work links translational control of an FMRP target mRNA, CaMKIIα, to the molecular-, cellular-, and circuit-level brain dysfunction in a complex neurodevelopmental disorder.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26670047      PMCID: PMC4685008          DOI: 10.1016/j.celrep.2015.11.013

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  48 in total

1.  Rapid redistribution of the postsynaptic density protein PSD-Zip45 (Homer 1c) and its differential regulation by NMDA receptors and calcium channels.

Authors:  S Okabe; T Urushido; D Konno; H Okado; K Sobue
Journal:  J Neurosci       Date:  2001-12-15       Impact factor: 6.167

Review 2.  Functional consequences of mutations in postsynaptic scaffolding proteins and relevance to psychiatric disorders.

Authors:  Jonathan T Ting; João Peça; Guoping Feng
Journal:  Annu Rev Neurosci       Date:  2012-04-20       Impact factor: 12.449

3.  Tetrameric hub structure of postsynaptic scaffolding protein homer.

Authors:  Mariko Kato Hayashi; Heather M Ames; Yasunori Hayashi
Journal:  J Neurosci       Date:  2006-08-16       Impact factor: 6.167

Review 4.  CaMKII: a molecular substrate for synaptic plasticity and memory.

Authors:  Brian C Shonesy; Nidhi Jalan-Sakrikar; Victoria S Cavener; Roger J Colbran
Journal:  Prog Mol Biol Transl Sci       Date:  2014       Impact factor: 3.622

5.  Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome.

Authors:  Emily K Osterweil; Dilja D Krueger; Kimberly Reinhold; Mark F Bear
Journal:  J Neurosci       Date:  2010-11-17       Impact factor: 6.167

6.  Phosphorylation of Homer3 by calcium/calmodulin-dependent kinase II regulates a coupling state of its target molecules in Purkinje cells.

Authors:  Akihiro Mizutani; Yukiko Kuroda; Akira Futatsugi; Teiichi Furuichi; Katsuhiko Mikoshiba
Journal:  J Neurosci       Date:  2008-05-14       Impact factor: 6.167

7.  Crystal structure of the Homer 1 family conserved region reveals the interaction between the EVH1 domain and own proline-rich motif.

Authors:  Katsumasa Irie; Toru Nakatsu; Kaoru Mitsuoka; Atsuo Miyazawa; Kenji Sobue; Yoko Hiroaki; Tomoko Doi; Yoshinori Fujiyoshi; Hiroaki Kato
Journal:  J Mol Biol       Date:  2002-05-10       Impact factor: 5.469

8.  Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice.

Authors:  Aubin Michalon; Michael Sidorov; Theresa M Ballard; Laurence Ozmen; Will Spooren; Joseph G Wettstein; Georg Jaeschke; Mark F Bear; Lothar Lindemann
Journal:  Neuron       Date:  2012-04-12       Impact factor: 17.173

9.  Interaction of Cupidin/Homer2 with two actin cytoskeletal regulators, Cdc42 small GTPase and Drebrin, in dendritic spines.

Authors:  Yoko Shiraishi-Yamaguchi; Yumi Sato; Rieko Sakai; Akihiro Mizutani; Thomas Knöpfel; Nozomu Mori; Katsuhiko Mikoshiba; Teiichi Furuichi
Journal:  BMC Neurosci       Date:  2009-03-24       Impact factor: 3.288

10.  Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome.

Authors:  Kwang-Mook Jung; Marja Sepers; Christopher M Henstridge; Olivier Lassalle; Daniela Neuhofer; Henry Martin; Melanie Ginger; Andreas Frick; Nicholas V DiPatrizio; Ken Mackie; Istvan Katona; Daniele Piomelli; Olivier J Manzoni
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

View more
  23 in total

1.  Calcium dysregulation and Cdk5-ATM pathway involved in a mouse model of fragile X-associated tremor/ataxia syndrome.

Authors:  Gaëlle Robin; José R López; Glenda M Espinal; Susan Hulsizer; Paul J Hagerman; Isaac N Pessah
Journal:  Hum Mol Genet       Date:  2017-07-15       Impact factor: 6.150

2.  A Novel Human CAMK2A Mutation Disrupts Dendritic Morphology and Synaptic Transmission, and Causes ASD-Related Behaviors.

Authors:  Jason R Stephenson; Xiaohan Wang; Tyler L Perfitt; Walker P Parrish; Brian C Shonesy; Christian R Marks; Douglas P Mortlock; Terunaga Nakagawa; James S Sutcliffe; Roger J Colbran
Journal:  J Neurosci       Date:  2017-01-27       Impact factor: 6.167

3.  Synaptic activity induces input-specific rearrangements in a targeted synaptic protein interaction network.

Authors:  Jonathan D Lautz; Emily A Brown; Alison A Williams VanSchoiack; Stephen E P Smith
Journal:  J Neurochem       Date:  2018-09       Impact factor: 5.372

Review 4.  A perspective on molecular signalling dysfunction, its clinical relevance and therapeutics in autism spectrum disorder.

Authors:  Sushmitha S Purushotham; Neeharika M N Reddy; Michelle Ninochka D'Souza; Nilpawan Roy Choudhury; Anusa Ganguly; Niharika Gopalakrishna; Ravi Muddashetty; James P Clement
Journal:  Exp Brain Res       Date:  2022-09-05       Impact factor: 2.064

Review 5.  Towards Kinase Inhibitor Therapies for Fragile X Syndrome: Tweaking Twists in the Autism Spectrum Kinase Signaling Network.

Authors:  Claudio D'Incal; Jitse Broos; Thierry Torfs; R Frank Kooy; Wim Vanden Berghe
Journal:  Cells       Date:  2022-04-13       Impact factor: 7.666

6.  Elevated ERK/p90 ribosomal S6 kinase activity underlies audiogenic seizure susceptibility in fragile X mice.

Authors:  Kirsty Sawicka; Alexander Pyronneau; Miranda Chao; Michael V L Bennett; R Suzanne Zukin
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-23       Impact factor: 11.205

7.  Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model.

Authors:  Christina Gross; Anwesha Banerjee; Durgesh Tiwari; Francesco Longo; Angela R White; A G Allen; Lindsay M Schroeder-Carter; Joseph C Krzeski; Nada A Elsayed; Rosemary Puckett; Eric Klann; Ralph A Rivero; Shannon L Gourley; Gary J Bassell
Journal:  Neuropsychopharmacology       Date:  2018-07-13       Impact factor: 7.853

Review 8.  The Complex Formed by Group I Metabotropic Glutamate Receptor (mGluR) and Homer1a Plays a Central Role in Metaplasticity and Homeostatic Synaptic Scaling.

Authors:  Joël Bockaert; Julie Perroy; Fabrice Ango
Journal:  J Neurosci       Date:  2021-06-30       Impact factor: 6.167

9.  Selective Disruption of Metabotropic Glutamate Receptor 5-Homer Interactions Mimics Phenotypes of Fragile X Syndrome in Mice.

Authors:  Weirui Guo; Gemma Molinaro; Katie A Collins; Seth A Hays; Richard Paylor; Paul F Worley; Karen K Szumlinski; Kimberly M Huber
Journal:  J Neurosci       Date:  2016-02-17       Impact factor: 6.167

10.  Restoring glutamate receptosome dynamics at synapses rescues autism-like deficits in Shank3-deficient mice.

Authors:  Sophie Sakkaki; Vincent Compan; Nathalie Bouquier; Enora Moutin; Federica Giona; Julie Areias; Elise Goyet; Anne-Laure Hemonnot-Girard; Vincent Seube; Bastien Glasson; Nathan Benac; Yan Chastagnier; Fabrice Raynaud; Etienne Audinat; Laurent Groc; Tangui Maurice; Carlo Sala; Chiara Verpelli; Julie Perroy
Journal:  Mol Psychiatry       Date:  2021-07-30       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.